Annual CFF
-$9.42 B
+$7.55 B+44.49%
31 December 2023
Summary:
Bristol-Myers Squibb annual cash flow from financing activities is currently -$9.42 billion, with the most recent change of +$7.55 billion (+44.49%) on 31 December 2023. During the last 3 years, it has risen by +$6.81 billion (+41.96%). BMY annual CFF is now -223.55% below its all-time high of $7.62 billion, reached on 31 December 2019.BMY Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$3.85 B
+$171.00 M+4.25%
30 September 2024
Summary:
Bristol-Myers Squibb quarterly cash flow from financing activities is currently -$3.85 billion, with the most recent change of +$171.00 million (+4.25%) on 30 September 2024. Over the past year, it has dropped by -$4.82 billion (-498.35%). BMY quarterly CFF is now -121.09% below its all-time high of $18.27 billion, reached on 30 June 2019.BMY Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$7.74 B
+$1.31 B+20.35%
30 September 2024
Summary:
Bristol-Myers Squibb TTM cash flow from financing activities is currently $7.74 billion, with the most recent change of +$1.31 billion (+20.35%) on 30 September 2024. Over the past year, it has increased by +$17.15 billion (+182.16%). BMY TTM CFF is now -48.22% below its all-time high of $14.94 billion, reached on 30 June 2019.BMY TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMY Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -498.4% | +182.2% |
| 3 y3 years | +42.0% | +2.9% | +147.7% |
| 5 y5 years | -223.6% | +49.8% | +1.5% |
BMY Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +44.5% | -126.3% | +31.9% | -6.5% | +143.8% |
| 5 y | 5 years | -223.6% | +44.5% | -126.3% | +49.8% | -10.0% | +143.8% |
| alltime | all time | -223.6% | +44.5% | -121.1% | +49.8% | -48.2% | +143.8% |
Bristol-Myers Squibb Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.85 B(-4.3%) | $7.74 B(+20.3%) |
| June 2024 | - | -$4.02 B(-127.5%) | $6.43 B(-22.3%) |
| Mar 2024 | - | $14.64 B(+1414.4%) | $8.28 B(-187.9%) |
| Dec 2023 | -$9.42 B(-44.5%) | $967.00 M(-118.7%) | -$9.42 B(-30.9%) |
| Sept 2023 | - | -$5.16 B(+137.5%) | -$13.63 B(+4.7%) |
| June 2023 | - | -$2.17 B(-28.8%) | -$13.01 B(-9.4%) |
| Mar 2023 | - | -$3.05 B(-6.0%) | -$14.36 B(-15.3%) |
| Dec 2022 | -$16.96 B(+4.5%) | -$3.25 B(-28.5%) | -$16.96 B(-4.1%) |
| Sept 2022 | - | -$4.54 B(+29.1%) | -$17.68 B(+18.5%) |
| June 2022 | - | -$3.52 B(-37.7%) | -$14.92 B(+2.3%) |
| Mar 2022 | - | -$5.65 B(+42.5%) | -$14.58 B(-10.1%) |
| Dec 2021 | -$16.22 B(+1309.6%) | -$3.97 B(+122.9%) | -$16.22 B(+84.9%) |
| Sept 2021 | - | -$1.78 B(-44.1%) | -$8.77 B(-8.4%) |
| June 2021 | - | -$3.18 B(-56.4%) | -$9.58 B(+29.6%) |
| Mar 2021 | - | -$7.29 B(-309.4%) | -$7.39 B(+542.2%) |
| Dec 2020 | -$1.15 B(-115.1%) | $3.48 B(-234.6%) | -$1.15 B(-90.7%) |
| Sept 2020 | - | -$2.59 B(+160.5%) | -$12.31 B(+15.4%) |
| June 2020 | - | -$993.00 M(-5.8%) | -$10.66 B(-224.1%) |
| Mar 2020 | - | -$1.05 B(-86.3%) | $8.60 B(+12.8%) |
| Dec 2019 | $7.62 B(-315.6%) | -$7.68 B(+715.8%) | $7.62 B(-48.2%) |
| Sept 2019 | - | -$941.00 M(-105.2%) | $14.72 B(-1.5%) |
| June 2019 | - | $18.27 B(-1000.3%) | $14.94 B(-444.1%) |
| Mar 2019 | - | -$2.03 B(+251.0%) | -$4.34 B(+22.8%) |
| Dec 2018 | -$3.54 B(-13.3%) | -$578.00 M(-19.7%) | -$3.54 B(-18.0%) |
| Sept 2018 | - | -$720.00 M(-29.1%) | -$4.31 B(+0.3%) |
| June 2018 | - | -$1.01 B(-16.9%) | -$4.29 B(+0.2%) |
| Mar 2018 | - | -$1.22 B(-9.6%) | -$4.29 B(+5.1%) |
| Dec 2017 | -$4.08 B(+53.7%) | -$1.35 B(+91.5%) | -$4.08 B(+22.4%) |
| Sept 2017 | - | -$706.00 M(-29.8%) | -$3.33 B(+5.0%) |
| June 2017 | - | -$1.01 B(-0.7%) | -$3.17 B(+16.7%) |
| Mar 2017 | - | -$1.01 B(+67.4%) | -$2.72 B(+2.4%) |
| Dec 2016 | -$2.65 B(-26.8%) | -$605.00 M(+10.8%) | -$2.65 B(-22.1%) |
| Sept 2016 | - | -$546.00 M(-1.1%) | -$3.41 B(-4.3%) |
| June 2016 | - | -$552.00 M(-41.9%) | -$3.56 B(-8.5%) |
| Mar 2016 | - | -$950.00 M(-30.1%) | -$3.89 B(+7.4%) |
| Dec 2015 | -$3.62 B(+48.7%) | -$1.36 B(+94.1%) | -$3.62 B(+45.2%) |
| Sept 2015 | - | -$700.00 M(-20.7%) | -$2.50 B(+7.4%) |
| June 2015 | - | -$883.00 M(+29.5%) | -$2.32 B(+20.6%) |
| Mar 2015 | - | -$682.00 M(+195.2%) | -$1.93 B(-20.9%) |
| Dec 2014 | -$2.44 B(+128.2%) | -$231.00 M(-56.3%) | -$2.44 B(+63.0%) |
| Sept 2014 | - | -$528.00 M(+8.6%) | -$1.50 B(-5.8%) |
| June 2014 | - | -$486.00 M(-59.2%) | -$1.59 B(-28.4%) |
| Mar 2014 | - | -$1.19 B(-267.7%) | -$2.22 B(+107.5%) |
| Dec 2013 | -$1.07 B(-75.4%) | $711.00 M(-214.7%) | -$1.07 B(-61.0%) |
| Sept 2013 | - | -$620.00 M(-44.4%) | -$2.74 B(-28.1%) |
| June 2013 | - | -$1.11 B(+2434.1%) | -$3.81 B(+7.5%) |
| Mar 2013 | - | -$44.00 M(-95.4%) | -$3.54 B(-18.3%) |
| Dec 2012 | -$4.33 B(+63.1%) | -$958.00 M(-43.3%) | -$4.33 B(+4.9%) |
| Sept 2012 | - | -$1.69 B(+98.7%) | -$4.13 B(+31.3%) |
| June 2012 | - | -$850.00 M(+1.7%) | -$3.14 B(+12.2%) |
| Mar 2012 | - | -$836.00 M(+10.9%) | -$2.80 B(+5.4%) |
| Dec 2011 | -$2.66 B(-20.5%) | -$754.00 M(+7.1%) | -$2.66 B(-25.5%) |
| Sept 2011 | - | -$704.00 M(+38.9%) | -$3.57 B(+0.2%) |
| June 2011 | - | -$507.00 M(-26.7%) | -$3.56 B(+0.3%) |
| Mar 2011 | - | -$692.00 M(-58.4%) | -$3.55 B(+6.2%) |
| Dec 2010 | -$3.34 B(>+9900.0%) | -$1.66 B(+138.4%) | -$3.34 B(+388.0%) |
| Sept 2010 | - | -$698.00 M(+41.0%) | -$685.00 M(+6.5%) |
| June 2010 | - | -$495.00 M(+1.9%) | -$643.00 M(-25.1%) |
| Mar 2010 | - | -$486.00 M(-148.9%) | -$858.00 M(+4947.1%) |
| Dec 2009 | -$17.00 M(-99.3%) | $994.00 M(-251.5%) | -$17.00 M(-98.9%) |
| Sept 2009 | - | -$656.00 M(-7.6%) | -$1.61 B(-49.1%) |
| June 2009 | - | -$710.00 M(-300.0%) | -$3.17 B(+112.5%) |
| Mar 2009 | - | $355.00 M(-158.9%) | -$1.49 B(-42.2%) |
| Dec 2008 | -$2.58 B(-19.6%) | -$603.00 M(-72.8%) | -$2.58 B(+3.2%) |
| Sept 2008 | - | -$2.21 B(-328.5%) | -$2.50 B(+17.3%) |
| June 2008 | - | $969.00 M(-232.0%) | -$2.13 B(-36.6%) |
| Mar 2008 | - | -$734.00 M(+40.1%) | -$3.37 B(+4.8%) |
| Dec 2007 | -$3.21 B | -$524.00 M(-71.6%) | -$3.21 B(-28.0%) |
| Sept 2007 | - | -$1.84 B(+598.5%) | -$4.46 B(+38.5%) |
| June 2007 | - | -$264.00 M(-54.6%) | -$3.22 B(-9.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2007 | - | -$581.00 M(-67.3%) | -$3.55 B(+5.8%) |
| Dec 2006 | -$3.35 B(-7.9%) | -$1.77 B(+193.9%) | -$3.35 B(-988.9%) |
| Sept 2006 | - | -$604.00 M(+2.9%) | $377.00 M(-19.1%) |
| June 2006 | - | -$587.00 M(+52.5%) | $466.00 M(-123.9%) |
| Mar 2006 | - | -$385.00 M(-119.7%) | -$1.95 B(-46.4%) |
| Dec 2005 | -$3.64 B(+685.5%) | $1.95 B(-479.2%) | -$3.64 B(-38.9%) |
| Sept 2005 | - | -$515.00 M(-82.8%) | -$5.96 B(+11.7%) |
| June 2005 | - | -$3.00 B(+44.7%) | -$5.33 B(+100.6%) |
| Mar 2005 | - | -$2.07 B(+466.7%) | -$2.66 B(+473.9%) |
| Dec 2004 | -$463.00 M(-55.1%) | -$366.00 M(-432.7%) | -$463.00 M(-21.5%) |
| Sept 2004 | - | $110.00 M(-133.6%) | -$590.00 M(-25.5%) |
| June 2004 | - | -$327.00 M(-372.5%) | -$792.00 M(-41.6%) |
| Mar 2004 | - | $120.00 M(-124.3%) | -$1.36 B(+31.5%) |
| Dec 2003 | -$1.03 B(-7.7%) | -$493.00 M(+435.9%) | -$1.03 B(+107.0%) |
| Sept 2003 | - | -$92.00 M(-89.7%) | -$498.00 M(-50.6%) |
| June 2003 | - | -$891.00 M(-300.2%) | -$1.01 B(+330.8%) |
| Mar 2003 | - | $445.00 M(+1012.5%) | -$234.00 M(-79.1%) |
| Dec 2002 | -$1.12 B(-163.2%) | $40.00 M(-106.6%) | -$1.12 B(-68.0%) |
| Sept 2002 | - | -$602.00 M(+414.5%) | -$3.49 B(-202.0%) |
| June 2002 | - | -$117.00 M(-73.3%) | $3.42 B(+39.5%) |
| Mar 2002 | - | -$438.00 M(-81.3%) | $2.45 B(+38.8%) |
| Dec 2001 | $1.77 B(-142.5%) | -$2.34 B(-137.0%) | $1.77 B(-42.2%) |
| Sept 2001 | - | $6.32 B(-681.0%) | $3.06 B(-171.9%) |
| June 2001 | - | -$1.09 B(-3.3%) | -$4.25 B(+0.5%) |
| Mar 2001 | - | -$1.12 B(+7.5%) | -$4.23 B(+1.8%) |
| Dec 2000 | -$4.16 B(+40.8%) | -$1.05 B(+4.8%) | -$4.16 B(+2.6%) |
| Sept 2000 | - | -$998.00 M(-6.2%) | -$4.05 B(+11.7%) |
| June 2000 | - | -$1.06 B(+1.4%) | -$3.63 B(+13.6%) |
| Mar 2000 | - | -$1.05 B(+11.4%) | -$3.19 B(+8.2%) |
| Dec 1999 | -$2.95 B(+11.7%) | -$942.00 M(+64.1%) | -$2.95 B(+33.6%) |
| Sept 1999 | - | -$574.00 M(-8.9%) | -$2.21 B(-2.0%) |
| June 1999 | - | -$630.00 M(-21.8%) | -$2.25 B(-14.5%) |
| Mar 1999 | - | -$806.00 M(+305.0%) | -$2.64 B(-0.2%) |
| Dec 1998 | -$2.64 B(+22.8%) | -$199.00 M(-67.9%) | -$2.64 B(-14.7%) |
| Sept 1998 | - | -$620.00 M(-38.7%) | -$3.10 B(+6.3%) |
| June 1998 | - | -$1.01 B(+24.5%) | -$2.91 B(+14.5%) |
| Mar 1998 | - | -$812.00 M(+24.3%) | -$2.54 B(+18.3%) |
| Dec 1997 | -$2.15 B(+14.1%) | -$653.00 M(+49.4%) | -$2.15 B(+21.2%) |
| Sept 1997 | - | -$437.00 M(-31.9%) | -$1.77 B(+2.7%) |
| June 1997 | - | -$642.00 M(+53.2%) | -$1.73 B(+4.0%) |
| Mar 1997 | - | -$419.00 M(+51.3%) | -$1.66 B(-11.8%) |
| Dec 1996 | -$1.89 B(+1.4%) | -$277.00 M(-29.2%) | -$1.89 B(-9.9%) |
| Sept 1996 | - | -$391.00 M(-32.0%) | -$2.09 B(-11.4%) |
| June 1996 | - | -$575.00 M(-10.4%) | -$2.36 B(+10.4%) |
| Mar 1996 | - | -$642.00 M(+32.9%) | -$2.14 B(+15.0%) |
| Dec 1995 | -$1.86 B(+13.4%) | -$483.00 M(-26.9%) | -$1.86 B(-6.3%) |
| Sept 1995 | - | -$661.00 M(+87.8%) | -$1.99 B(+53.8%) |
| June 1995 | - | -$352.00 M(-3.0%) | -$1.29 B(-16.2%) |
| Mar 1995 | - | -$363.00 M(-40.4%) | -$1.54 B(-6.0%) |
| Dec 1994 | -$1.64 B(-3.6%) | -$609.00 M(-1945.5%) | -$1.64 B(+5.3%) |
| Sept 1994 | - | $33.00 M(-105.5%) | -$1.56 B(-28.1%) |
| June 1994 | - | -$602.00 M(+30.6%) | -$2.17 B(+28.2%) |
| Mar 1994 | - | -$461.00 M(-12.5%) | -$1.69 B(-0.6%) |
| Dec 1993 | -$1.70 B(-2.7%) | -$527.00 M(-8.5%) | -$1.70 B(+10.1%) |
| Sept 1993 | - | -$576.00 M(+360.8%) | -$1.54 B(+16.8%) |
| June 1993 | - | -$125.00 M(-73.5%) | -$1.32 B(-20.9%) |
| Mar 1993 | - | -$472.00 M(+27.2%) | -$1.67 B(-4.4%) |
| Dec 1992 | -$1.75 B(+10.8%) | -$371.00 M(+4.8%) | -$1.75 B(-2.1%) |
| Sept 1992 | - | -$354.00 M(-25.3%) | -$1.78 B(+1.5%) |
| June 1992 | - | -$474.00 M(-13.7%) | -$1.76 B(+9.9%) |
| Mar 1992 | - | -$549.00 M(+34.6%) | -$1.60 B(+1.5%) |
| Dec 1991 | -$1.58 B(+5.6%) | -$408.00 M(+24.8%) | -$1.58 B(+1.9%) |
| Sept 1991 | - | -$327.00 M(+3.5%) | -$1.55 B(-8.6%) |
| June 1991 | - | -$316.00 M(-39.9%) | -$1.69 B(-0.9%) |
| Mar 1991 | - | -$526.00 M(+38.8%) | -$1.71 B(+14.5%) |
| Dec 1990 | -$1.49 B(+48.2%) | -$379.00 M(-19.9%) | -$1.49 B(+34.0%) |
| Sept 1990 | - | -$473.00 M(+42.5%) | -$1.11 B(+73.7%) |
| June 1990 | - | -$332.00 M(+7.1%) | -$642.00 M(+107.1%) |
| Mar 1990 | - | -$310.00 M | -$310.00 M |
| Dec 1989 | -$1.01 B | - | - |
FAQ
- What is Bristol-Myers Squibb annual cash flow from financing activities?
- What is the all time high annual CFF for Bristol-Myers Squibb?
- What is Bristol-Myers Squibb quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Bristol-Myers Squibb?
- What is Bristol-Myers Squibb quarterly CFF year-on-year change?
- What is Bristol-Myers Squibb TTM cash flow from financing activities?
- What is the all time high TTM CFF for Bristol-Myers Squibb?
- What is Bristol-Myers Squibb TTM CFF year-on-year change?
What is Bristol-Myers Squibb annual cash flow from financing activities?
The current annual CFF of BMY is -$9.42 B
What is the all time high annual CFF for Bristol-Myers Squibb?
Bristol-Myers Squibb all-time high annual cash flow from financing activities is $7.62 B
What is Bristol-Myers Squibb quarterly cash flow from financing activities?
The current quarterly CFF of BMY is -$3.85 B
What is the all time high quarterly CFF for Bristol-Myers Squibb?
Bristol-Myers Squibb all-time high quarterly cash flow from financing activities is $18.27 B
What is Bristol-Myers Squibb quarterly CFF year-on-year change?
Over the past year, BMY quarterly cash flow from financing activities has changed by -$4.82 B (-498.35%)
What is Bristol-Myers Squibb TTM cash flow from financing activities?
The current TTM CFF of BMY is $7.74 B
What is the all time high TTM CFF for Bristol-Myers Squibb?
Bristol-Myers Squibb all-time high TTM cash flow from financing activities is $14.94 B
What is Bristol-Myers Squibb TTM CFF year-on-year change?
Over the past year, BMY TTM cash flow from financing activities has changed by +$17.15 B (+182.16%)